Insider Trading Activity Intellia Therapeutics (NASDAQ:NTLA) – Director Sold 6,686 shares of Stock

Insider Trading Activity For Intellia Therapeutics (NASDAQ:NTLA)

Jean Francois Formela , Director of Intellia Therapeutics (NASDAQ:NTLA) reportedly Sold 6,686 shares of the company’s stock at an average price of 25.04 for a total transaction amount of $167,417.44 SEC Form

Insider Trading History For Intellia Therapeutics (NASDAQ:NTLA)

On 5/11/2016 Institutes For Biomed Novartis, Major Shareholder, bought 277,777 with an average share price of $18.00 per share and the total transaction amounting to $4,999,986.00.

On 5/11/2016 Carl L Gordon, Director, bought 250,000 with an average share price of $18.00 per share and the total transaction amounting to $4,500,000.00.

On 5/11/2016 Bros. Advisors Lp Baker, Insider, bought 200,000 with an average share price of $18.00 per share and the total transaction amounting to $3,600,000.00.

On 3/10/2017 Jean Francois Formela, Director, sold 21,132 with an average share price of $13.91 per share and the total transaction amounting to $293,946.12.

On 7/11/2017 Venture Fund Ix L.P. Atlas, Major Shareholder, sold 150,000 with an average share price of $16.24 per share and the total transaction amounting to $2,436,000.00.

On 12/6/2017 Nessan Bermingham, CEO, sold 111,500 with an average share price of $20.34 per share and the total transaction amounting to $2,267,910.00.

On 12/8/2017 Nessan Bermingham, CEO, sold 336,783 with an average share price of $20.78 per share and the total transaction amounting to $6,998,350.74.

Analyst Ratings History For Intellia Therapeutics (NASDAQ:NTLA)

• On 9/28/2016 Janney Montgomery Scott Initiated Coverage of rating Buy with a price target of $29.00
• On 10/31/2017 Jefferies Group Set Price Target of rating Buy ➝ Buy with a price target of $36.00 ➝ $42.00
• On 11/3/2017 Credit Suisse Group Boost Price Target of rating Outperform with a price target of $24.00 ➝ $28.00
• On 12/18/2017 Oppenheimer Reiterated Rating Hold
• On 3/7/2018 Barclays Boost Price Target of rating Overweight ➝ Overweight with a price target of $33.00 ➝ $46.00
• On 3/8/2018 JMP Securities Initiated Coverage of rating Mkt Outperform ➝ Outperform
• On 3/14/2018 Leerink Swann Reiterated Rating Outperform

Recent Trading Activity for Intellia Therapeutics (NASDAQ:NTLA)
Shares of Intellia Therapeutics closed the previous trading session at 25.48 up +0.19 0.73% with 25.200000762939453 shares trading hands.